<DOC>
	<DOCNO>NCT00882713</DOCNO>
	<brief_summary>This single arm study ass efficacy , safety tolerability monthly administration subcutaneous Mircera maintenance hemoglobin level dialysis patient chronic renal anemia . Patients receive subcutaneous Mircera start dose 120 , 200 360 microgram every 4 week , calculate last weekly dose epoetin darbepoetin alfa previously administer . Subsequent dos adjust maintain hemoglobin level within target range . Treatment duration 56 week , target sample size 200 individual .</brief_summary>
	<brief_title>A Study Once Monthly Subcutaneous Mircera Dialysis Patients With Chronic Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient &gt; =18 year age ; chronic renal anemia ; regular longterm hemodialysis peritoneal dialysis , mode dialysis &gt; =3 month ; continuous iv maintenance epoetin alfa therapy dose interval previous 2 month . transfusion red blood cell previous 2 month ; poorly control hypertension ; significant acute chronic bleeding ; active malignant disease ( except nonmelanoma skin cancer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>